{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:35:02Z","timestamp":1777865702316,"version":"3.51.4"},"reference-count":89,"publisher":"The Royal Society","issue":"1949","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Just three classes of antifungals are available for the treatment of WHO critical priority fungal pathogens Cryptococcus, Candida and Aspergillus spp. Drug development and optimization via phase II and III clinical trials is reliant on binary composite endpoints (clinical\/radiological\/mycological), requiring large patient cohorts with challenging logistics at great expense. The validation and implementation of continuous mycological treatment response biomarkers have the potential to facilitate smaller investigator-led trials to optimize existing and novel drugs and combinations, as demonstrated in cryptococcal meningitis, where early fungicidal activity is now a primary endpoint in phase II trials and a secondary endpoint in phase III trials. In invasive aspergillosis, serum galactomannan holds promise: numerous studies show a decline on treatment to be associated with clinical outcome, however, further prospective, standardized studies are required before inclusion in clinical trial response criteria. In invasive candidiasis, while beta-D-glucan (BDG) and qPCR in invasive candidiasis decline during treatment, studies are limited to inadequately powered retrospective cohorts with simple correlation analyses. We include preliminary data from our ongoing prospective study showing an overall decline on treatment, with qPCR clearing more rapidly than BDG, with considerable heterogeneity of kinetics in this complex population. Future analyses must account for baseline values and inter-patient variation.<\/jats:p>\n                  <jats:p>This article is part of the Theo Murphy meeting issue \u2018Evaluating anti-infective drugs\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0341","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:17:38Z","timestamp":1777533458000},"source":"Crossref","is-referenced-by-count":0,"title":["The application of treatment response biomarkers in clinical trials for cryptococcosis, invasive aspergillosis and candidiasis"],"prefix":"10.1098","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8713-3796","authenticated-orcid":false,"given":"Phoebe","family":"Allebone-Salt","sequence":"first","affiliation":[{"name":"St George's University of London 1 , ,","place":["London, UK, SW12 0RE"],"department":["Institute of Infection and Immunity"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wake","sequence":"additional","affiliation":[{"name":"St George's University of London 1 , ,","place":["London, UK, SW12 0RE"],"department":["Institute of Infection and Immunity"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Lewis","family":"White","sequence":"additional","affiliation":[{"name":"Public Health Wales Mycology Reference Laboratory 2 , ,","place":["Cardiff, UK, CF14 4XW"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Price","sequence":"additional","affiliation":[{"name":"Public Health Wales Mycology Reference Laboratory 2 , ,","place":["Cardiff, UK, CF14 4XW"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Harrison","sequence":"additional","affiliation":[{"name":"St George's University of London 1 , ,","place":["London, UK, SW12 0RE"],"department":["Institute of Infection and Immunity"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2676-838X","authenticated-orcid":false,"given":"Tihana","family":"Bicanic","sequence":"additional","affiliation":[{"name":"St George's University of London 1 , ,","place":["London, UK, SW12 0RE"],"department":["Institute of Infection and Immunity"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"175","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026043003173354900_R1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"2026043003173354900_R2","unstructured":"World Health Organisation\n          . 2022WHO fungal priority pathogens list to guide research, development and public health action. Seehttps:\/\/www.who.int\/publications\/i\/item\/9789240060241."},{"key":"2026043003173354900_R3","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R4","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S1473-3099(23)00731-4","article-title":"Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM","volume":"24","author":"Chang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"2026043003173354900_R8","unstructured":"Basilea Pharmaceutica\n          . 2025An interventional efficacy and safety phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and\/or invasive candidiasis. Report no. NCT05421858. Seehttps:\/\/clinicaltrials.gov\/study\/NCT05421858."},{"key":"2026043003173354900_R9","unstructured":"F2G Biotech GmbH\n          . Phase III randomised study to evaluate efficacy and safety of treatment with olorofim versus treatment with Ambisome\u00ae followed by standard of care in patients with invasive fungal disease caused by aspergillus species. Report no. NCT05101187. Seehttps:\/\/clinicaltrials.gov\/study\/NCT05101187."},{"key":"2026043003173354900_R10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2125.2005.02435.x","article-title":"Biomarkers and surrogate endpoints","volume":"59","author":"Aronson","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026043003173354900_R11","unstructured":"US Food and Drug Administration\n          . 2024Surrogate endpoint resources for drug and biologic development. Seehttps:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development."},{"key":"2026043003173354900_R12","unstructured":"US Food and Drug Administration\n          . 2024Table of surrogate endpoints that were the basis of drug approval or licensure. Seehttps:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure."},{"key":"2026043003173354900_R13","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac112","article-title":"Noninvasive testing and surrogate markers in invasive fungal diseases","volume":"9","author":"Thompson","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"2026043003173354900_R14","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R15","unstructured":"IMMY\n           . CrAg\u00ae cryptococcal antigen lateral flow assay. Norman, OK: Immuno-Mycologics Inc. Seehttps:\/\/www.immy.com\/crag-cryptococcal-antigen-lateral-flow-assay-fungal-test."},{"key":"2026043003173354900_R16","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"2026043003173354900_R17","unstructured":"World Health Organisation\n          . 2018Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Seehttps:\/\/www.who.int\/publications\/i\/item\/9789241550277."},{"key":"2026043003173354900_R18","unstructured":"World Health Organisation\n          . 2022Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Seehttps:\/\/www.who.int\/publications\/i\/item\/9789240052178."},{"key":"2026043003173354900_R19","unstructured":"Clinton Health Access Initiative (CHAI)\n          . 2023HIV Market Report. p. 23. Report no. 14. Seehttps:\/\/www.clintonhealthaccess.org\/report\/2023-hiv-market-report-the-state-of-hiv-market-in-low-and-middle-income-countries\/."},{"key":"2026043003173354900_R20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S1473-3099(22)00234-1","article-title":"Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study","volume":"22","author":"Mashau","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R21","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2352-3018(23)00182-0","article-title":"Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study","volume":"10","author":"Mfinanga","year":"2023","journal-title":"Lancet HIV"},{"key":"2026043003173354900_R22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJM198708063170602","article-title":"Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks","volume":"317","author":"Dismukes","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","article-title":"Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis","volume":"326","author":"Saag","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/0003-4819-113-3-183","article-title":"Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial","volume":"113","author":"Larsen","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"2026043003173354900_R26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome","volume":"337","author":"van der Horst","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199102283240902","article-title":"A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group","volume":"324","author":"Bozzette","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R29","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","article-title":"Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda","volume":"47","author":"Longley","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI124516","article-title":"Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis","volume":"129","author":"Stone","year":"2019","journal-title":"J. Clin. Investig."},{"key":"2026043003173354900_R32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","article-title":"A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis","volume":"26","author":"Jackson","year":"2012","journal-title":"AIDS"},{"key":"2026043003173354900_R33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/ciy515","article-title":"Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial","volume":"68","author":"Jarvis","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R36","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/cid\/cit794","article-title":"Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes","volume":"58","author":"Jarvis","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/mmy\/myv104","article-title":"Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis","volume":"54","author":"Dyal","year":"2016","journal-title":"Med. Mycol."},{"key":"2026043003173354900_R39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R40","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"2026043003173354900_R41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cir745","article-title":"Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis","volume":"54","author":"Loyse","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R42","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/cid\/ciaa016","article-title":"Cerebrospinal fluid early fungicidal activity as a surrogate endpoint for cryptococcal meningitis survival in clinical trials","volume":"71","author":"Pullen","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159727","article-title":"Early fungicidal activity as a candidate surrogate endpoint for all-cause mortality in cryptococcal meningitis: a systematic review of the evidence","volume":"11","author":"Montezuma-Rusca","year":"2016","journal-title":"PLoS One"},{"key":"2026043003173354900_R45","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat. Med."},{"key":"2026043003173354900_R46","article-title":"Clinical trials response criteria for cryptococcosis: consensus guidance by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology","author":"Boulware","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R47","doi-asserted-by":"crossref","first-page":"e00140","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and aspergillosis in 2019","volume":"33","author":"Latg\u00e9","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"2026043003173354900_R48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0255-0857.108717","article-title":"Variables affecting the performance of galactomannan assay in high-risk patients at a tertiary care centre in India","volume":"31","author":"Khanna","year":"2013","journal-title":"Indian J. Med. Microbiol."},{"key":"2026043003173354900_R49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090176","article-title":"Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis","volume":"9","author":"Chai","year":"2014","journal-title":"PLoS One"},{"key":"2026043003173354900_R50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R51","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","article-title":"Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases","volume":"72","author":"Mercier","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R52","article-title":"Submitted. Revised definitions of responses to therapy and study outcomes in clinical trials of aspergillosis and rare mould infections: Mycoses Study Group and European Confederation of Medical Mycology consensus criteria","author":"Hoenigl","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106229","article-title":"Attributable mortality of candidemia\u2014results from the ECMM Candida III multinational European Observational Cohort study","volume":"89","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"J. Infect."},{"key":"2026043003173354900_R54","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1111\/j.1469-0691.2012.03777.x","article-title":"Post-diagnostic kinetics of the (1 \u2192 3)-\u03b2-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia","volume":"18","author":"Koo","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"2026043003173354900_R55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/cid\/ciad141","article-title":"Clinical impact of polymerase chain reaction-based aspergillus and azole resistance detection in invasive aspergillosis: a prospective multicenter study","volume":"77","author":"Huygens","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R56","unstructured":"Shamsuddin\n              H\n            \n          . Use of serum Aspergillus galactomannan antigen as a biomarker of invasive aspergillosis in patients with hematologic malignancy and recipients of allogeneic hematopoietic stem cell transplants for the purpose of treatment development. Seehttps:\/\/www.fda.gov\/media\/89999\/download."},{"key":"2026043003173354900_R57","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1086\/528714","article-title":"Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications","volume":"46","author":"Miceli","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R58","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.04723-14","article-title":"Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus","volume":"59","author":"Al-Nakeeb","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003173354900_R59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/infdis\/169.2.356","article-title":"Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection","volume":"169","author":"Francis","year":"1994","journal-title":"J. Infect. Dis."},{"key":"2026043003173354900_R60","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/AAC.45.3.857-869.2001","article-title":"Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia","volume":"45","author":"Petraitiene","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026043003173354900_R61","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2018.00661","article-title":"Galactomannan, a surrogate marker for outcome in invasive aspergillosis: finally coming of age","volume":"9","author":"Mercier","year":"2018","journal-title":"Front. Microbiol"},{"key":"2026043003173354900_R62","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/JCM.00750-11","article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","volume":"50","author":"Bergeron","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"2026043003173354900_R63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/339324","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease","volume":"34","author":"Boutboul","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R64","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/JCM.02281-09","article-title":"Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis","volume":"48","author":"Koo","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"2026043003173354900_R65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5603\/AIT.2014.0027","article-title":"Prognostic value of serum galactomannan in mixed ICU patients: a retrospective observational study","volume":"46","author":"Teering","year":"2014","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"2026043003173354900_R66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129022","article-title":"Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis","volume":"10","author":"Neofytos","year":"2015","journal-title":"PLoS One"},{"key":"2026043003173354900_R67","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jac\/dkad139","article-title":"Invasive candidiasis: current clinical challenges and unmet needs in adult populations","volume":"78","author":"Soriano","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"2026043003173354900_R68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00503-3","article-title":"Invasive candidiasis","volume":"10","author":"Lass-Fl\u00f6rl","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2026043003173354900_R69","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty Years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"2026043003173354900_R70","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(24)00749-7","article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","volume":"25","author":"Cornely","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"2026043003173354900_R71","unstructured":"Scynexis Inc\n          . 2023A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and\/or invasive candidiasis: intravenous echinocandin followed by oral ibrexafungerp versus intravenous echinocandin followed by oral fluconazole (MARIO). Report no. NCT05178862. Seehttps:\/\/clinicaltrials.gov\/study\/NCT05178862."},{"key":"2026043003173354900_R72","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the 'missing 50%' of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R73","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1128\/JCM.00609-11","article-title":"Quantitation of Candida CFU in initial positive blood cultures","volume":"49","author":"Pfeiffer","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"2026043003173354900_R74","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad028","article-title":"Time-to-positivity in bloodstream infection for Candida species as a prognostic marker for mortality","volume":"61","author":"Keighley","year":"2023","journal-title":"Med. Mycol."},{"key":"2026043003173354900_R75","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2026043003173354900_R76","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med."},{"key":"2026043003173354900_R77","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1007\/s10620-019-05581-y","article-title":"Gut leakage of fungal-derived inflammatory mediators: part of a gut-liver-kidney axis in bacterial sepsis","volume":"64","author":"Amornphimoltham","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"2026043003173354900_R78","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/cid\/cis456","article-title":"(1,3)-\u03b2-D-glucan as a prognostic marker of treatment response in invasive candidiasis","volume":"55","author":"Jaijakul","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"2026043003173354900_R79","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1164\/rccm.201211-2069OC","article-title":"\u03b2-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis","volume":"188","author":"Tissot","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2026043003173354900_R80","doi-asserted-by":"crossref","first-page":"e00598","DOI":"10.1128\/jcm.00598-23","article-title":"Detailed \u03b2-(1\u21923)-D-glucan and mannan antigen kinetics in patients with candidemia","volume":"61","author":"Tr\u00e4ger","year":"2023","journal-title":"J. Clin. Microbiol."},{"key":"2026043003173354900_R81","doi-asserted-by":"crossref","DOI":"10.1186\/cc13953","article-title":"Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and Candida colonisation","volume":"18","author":"Poissy","year":"2014","journal-title":"Crit. Care"},{"key":"2026043003173354900_R82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/JCM.01602-10","article-title":"PCR diagnosis of invasive candidiasis: systematic review and meta-analysis","volume":"49","author":"Avni","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"2026043003173354900_R83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12281-021-00421-x","article-title":"Molecular diagnosis of yeast infections","volume":"15","author":"White","year":"2021","journal-title":"Curr. Fungal Infect. Rep."},{"key":"2026043003173354900_R84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7883\/yoken.JJID.2009.1","article-title":"Early detection of systemic candidiasis in the whole blood of patients with hematologic malignancies","volume":"62","author":"Badiee","year":"2009","journal-title":"Jpn. J. Infect. Dis."},{"key":"2026043003173354900_R85","unstructured":"Badiee\n              P\n            , KordbachehP, AlborziA. 2025Experimental and clinical transplantation. Seehttps:\/\/www.ectrx.org\/forms\/ectrxcontentshow.php?year=2007&volume=5&issue=1&supplement=0&makale_no=0&spage_number=624&content_type=FULL%20TEXT."},{"key":"2026043003173354900_R86","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2666-5247(23)00362-2","article-title":"Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study","volume":"5","author":"Mbangiwa","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026043003173354900_R87","doi-asserted-by":"crossref","DOI":"10.3390\/jof8090935","article-title":"An evaluation of the OLM CandID real-time PCR to aid in the diagnosis of invasive candidiasis when testing serum samples","volume":"8","author":"Price","year":"2022","journal-title":"J. Fungi"},{"key":"2026043003173354900_R88","article-title":"phoebeas\/philtransbcandirescode: philtransbcandirescode v1_public (v1.0.1)","author":"phoebeas","year":"2025","journal-title":"Zenodo"},{"key":"2026043003173354900_R89","article-title":"Supplementary material from: The application of treatment response biomarkers in clinical trials for cryptococcosis, invasive aspergillosis and candidiasis. Figshare.","author":"Allebone-Salt","year":"2026"}],"container-title":["Philosophical Transactions B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0341\/6135620\/rstb.2024.0341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0341\/6135620\/rstb.2024.0341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:17:56Z","timestamp":1777533476000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1949\/20240341\/481553\/The-application-of-treatment-response-biomarkers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":89,"journal-issue":{"issue":"1949","published-online":{"date-parts":[[2026,4,30]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0341","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"20240341"}}